CV
NASDAQCapsoVision Inc.
Price$6.55+0.60 (+10.08%)
2026-04-212026-07-24
News · 26 weeks44-75%
2026-02-012026-07-26
Mix2590d
- Insider16(64%)
- SEC Filings5(20%)
- Earnings2(8%)
- Other1(4%)
- Leadership1(4%)
Latest news
25 items- INSIDERLarge owner Harari Eliyahou Et Al bought $410,988 worth of shares (61,068 units at $6.73) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERLarge owner Harari Eliyahou Et Al bought $495,117 worth of shares (81,300 units at $6.09) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERLarge owner Harari Eliyahou Et Al bought $101,811 worth of shares (13,850 units at $7.35) (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Director Shields David Stanley4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERNew insider Shields David Stanley claimed no ownership of stock in the company (SEC Form 3)3 - CapsoVision, Inc (0001378325) (Issuer)
- SECCapsoVision Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of DirectorsSARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, announced the appointment of David S. Shields, M.D., to its Board of Directors, effective July 1, 2026. Dr. Shields is a board-certified gastroenterologist with more than 40 years of experience in academic medicine, clinical gastroenterology, advanced endoscopy and digestive disease management. He has served as a clinical advisor and consultant to CapsoVision for nearly a decade. He succeeds Joanne C. Imperial, M.D., who has stepped down from the Board and will continue to support the Compan
- INSIDERDirector Imperial Joanne Carol exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 120% to 3,709 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERAmendment: Director Imperial Joanne Carol sold $8,587 worth of shares (1,200 units at $7.16), decreasing direct ownership by 42% to 1,687 units (SEC Form 4)4/A - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Tsai Chen Lung exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 70% to 4,929 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Kuo Hui Ying exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 15% to 15,263 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector King Wen-Herng Henry exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 9% to 25,619 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Harari Michele exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 3% to 61,065 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Gouw Julia S exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 70% to 4,909 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- SECSEC Form 8-K filed by CapsoVision Inc.8-K - CapsoVision, Inc (0001378325) (Filer)
- INSIDERSEC Form 4 filed by Officer Wang Kang-Huai4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Sr. VP of Finance Garcia David Michael4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Head of Global Sales Atkinson Douglas Patrick4 - CapsoVision, Inc (0001378325) (Issuer)
- SECSEC Form 10-Q filed by CapsoVision Inc.10-Q - CapsoVision, Inc (0001378325) (Filer)
- SECCapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision Reports First Quarter 2026 Financial ResultsSARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026. Recent Highlights Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health Systems
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CapsoVision Inc.SCHEDULE 13G/A - CapsoVision, Inc (0001378325) (Subject)
- INSIDERHead of Global Sales Atkinson Douglas Patrick exercised 107,357 shares at a strike of $0.42 (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- PRCapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 5439091. The live and archived webcast of the
- SECSEC Form DEF 14A filed by CapsoVision Inc.DEF 14A - CapsoVision, Inc (0001378325) (Filer)
CV FAQ
6 questionsWhere does CV stock trade?
CapsoVision Inc. (CV) is listed on NASDAQ.What sector and industry is CV in?
CapsoVision Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did CapsoVision Inc. go public?
CapsoVision Inc. (CV) completed its IPO in 2025.What are analysts saying about CV?
CapsoVision Inc. has had 2 recent analyst actions on file. The most recent action was from The Benchmark Company: Speculative Buy with a $500.00 price target on 2025-07-28. Recent price targets range from $500.00 to $600.00.What companies are similar to CV?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare CV side-by-side with any of them on Quantisnow.How can I track CV on Quantisnow?
Quantisnow aggregates CapsoVision Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CV to receive live email and push alerts on every new disclosure.